Genmab CEO sees M&A potential in new partnership with Argenx for antibody discovery.

Genmab, a Danish antibody specialist with a $27 billion market cap, has announced a multi-year research deal with Dutch drugmaker argenx to enter the immunology and inflammation market. The companies will split expenses and potential upside and start researching two undisclosed targets in cancer and immunology, though it could grow to more targets over time. Genmab CEO Jan van de Winkel touts M&A potential as the company expands beyond oncology.